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Background: Vascular endothelial growth factor (VEGF) plays a major role in angiogenesis. One of the functions of
VEGF is to regulate neovascularization in clear cell renal cell carcinoma (CCRCC). The objective of our study was to
examine whether before nephrectomy serum levels of VEGF or expression of VEGF using immunohistochemistry
(IHC) could predict postoperative recurrence in nonmetastatic CCRCC.
Results: Twelve patients (14.5%) had recurrence during a mean follow-up of 52.6 ± 31.2 months. The serum VEGF
level was significantly higher in patients with recurrence than in those without recurrence (P = 0.038). High serum
VEGF levels were above 416 pg/mL; this value was chosen based on a receiver operating characteristic analysis. The
recurrence-free survival rate in patients with a high serum VEGF level was significantly lower than in those with a
low serum VEGF level (P = 0.003). In total, tumors from 26 patients (31.3%) showed overexpression of VEGF using
IHC. The recurrence-free survival rate in the IHC-positive group was significantly lower than that in the IHC-negative
group (P = 0.044). Multivariate analysis indicated that preoperative serum VEGF levels (P = 0.013) and female gender
(P = 0.004) were independent predictors of postoperative recurrence in nonmetastatic CCRCC.
Conclusions: Preoperative serum VEGF levels is a useful predictor compared with IHC analysis of VEGF of
postoperative recurrence in nonmetastatic CCRCC.
Keywords: Recurrence, Renal cell carcinoma, Vascular endothelial growth factor, NephrectomyBackground
Clear cell renal cell carcinoma (CCRCC) is characterized
by inactivation of the von Hipple-Lindau (VHL) pathway
caused by somatic mutations or methylation of the VHL
gene in the majority of patients. The VHL gene product
is involved in the regulation of a transcription factor
called hypoxia-inducible factor (HIF), which is a hetero-
dimer of an α and β subunit. In cells with deficient or
aberrant VHL protein, HIFα accumulates and binds to
HIFβ. The resultant increased production of vascular
endothelial growth factor (VEGF) is considered to be
fundamental to the highly angiogenic nature of CCRCC* Correspondence: toke@ks.kyorin-u.ac.jp
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unless otherwise stated.and critical to oncogenesis [1,2]. Anti-angiogenesis treat-
ment for CCRCC includes the use of several inhibitors of
VEGF and its cognate receptor VEGF receptor (VEGFR) 2
that have dramatic antitumor activity in CCRCC [3]. Several
studies have reported that some molecular markers (tissue
Ki-67, tissue p53, tissue VEGFR-1, tissue VEGF-D and
serum carbonic anhydrase IX) could predict disease-free
survival after nephrectomy for nonmetastatic CCRCC [4,5].
Studies have shown that serum levels of VEGF and
tumor VEGF expression are useful predictors of progno-
sis in RCC [6-8]. However, to our knowledge, there have
been very few reports regarding the association between
VEGF and recurrence after nephrectomy in nonmetastatic
CCRCC [5,9]. Previously, we reported that the pretreat-
ment serum level of VEGF correlated with postoperative
recurrence in patients with nonmetastatic CCRCC [9]. Intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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serum VEGF levels and expression of VEGF, assessed
using immunohistochemistry (IHC), could predict postop-
erative recurrence in patients with nonmetastatic CCRCC.
The discovery of reliable biomarkers in CCRCC could
have an important impact on diagnosis, prognosis and
prediction of therapeutic benefit.
Methods
Patients
A total of 83 patients with nonmetastatic CCRCC, who
underwent radical nephrectomy at the Kyorin University
Hospital between August 2001 and March 2010, were
enrolled in the study. Initial clinical stage determination
consisted of a physical examination, computed tomog-
raphy (CT) and a bone scan. Data on variables such as
age, gender, tumor stage, pathological grade, histological
vein invasion, tumor size, tumor necrosis, Eastern Co-
operative Oncology Group performance status (ECOG
PS), symptoms (flank pain, flank mass, and hematuria),
UCLA Integrated Staging System (UISS) [10] and bio-
chemical parameters [e.g., levels of hemoglobin (Hb), lac-
tate dehydrogenase (LDH), calcium (Ca) and C-reactive
protein (CRP)] were collected. Tumor stage was deter-
mined on the basis of the 2009 TNM classification of the
Union for International Cancer Control. Pathological
grade was determined on the basis of the General Rules
for Clinical and Pathological Studies on Renal Cell
Carcinoma in Japan (pathological grade was classified
as G1–G3). UISS incorporates the 1997 TNM classifi-
cation, ECOG PS and pathological grade [10]. The cut-
off level of LDH was determined to be 1.5 times the
upper limit of normal (ULN). Corrected serum Ca was
calculated as follows: total Ca + (4 − albumin). Tumor size,
CRP and anemia were dichotomized as follows: tumor
size, <5 cm vs. ≥5 cm, CRP, ≤1.0 vs. >1.0 mg/dL, and
anemia, ≤13 vs. >13 g/dL in males and ≤11.5 vs. >11.5 g/dL
in females [11,12]. The Ethics Committee of the University
of Kyorin approved this study. Informed consent was
obtained from all patients.
Blood samples
Serum samples were obtained before nephrectomy from a
peripheral vein. An 8.5 mL blood sample was taken and
after clotting, the blood sample was centrifuged at
2000 rpm for 10 min. Serum was then stored at -80°C in
1 mL aliquots until analysis. A VEGF assay was performed
using a commercial quantitative immunoassay kit for hu-
man VEGF165 (Quantikine, Human VEGF immunoassay,
R&S Systems, Minneapolis, MN, USA). Serum samples
(100 μL) were added to a 96-well microtiter plate coated
with purified antihuman VEGF mouse IgG monoclonal
antibodies and incubated at room temperature for 2 h.
After washing, 200 μL of the secondary antibody solution,containing VEGF-specific polyclonal goat antibodies,
was added and incubated for 2 h at room temperature.
Substrate solution was added and the reaction contin-
ued for 25 min. Absorbance was measured at 450 nm
using a microtiter plate reader (EMax, Molecular Devices,
Sunnyvale, CA, USA). The sensitivity of the assay was
9 pg/ml, and coefficients of variance ranged from 4.5–
6.7% and from 6.2–8.8% within and between assays,
respectively.
Tissue samples
Paraffin block sections were available for all cases.
Representative hematoxylin and eosin-stained specimens
were reviewed to assess the histological type, histological
vein invasion, tumor necrosis and pathological grade as
well as to select sections for IHC. Cancer tissue samples
for IHC analysis were selected from the site of highest
pathological grade.
IHC
IHC was performed on 5 μm paraffin-embedded tissue
sections placed on poly-L-lysine-coated glass slides.
After heat drying, sections were deparaffinized in xylene
and rehydrated in a series of graded ethanol solutions.
Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide for 5 min at room temperature. For antigen re-
trieval, sections were immersed in a 0.01 mol/L sodium
citrate buffer (pH 6.0), heated in a 600 W microwave
for 4 min (twice) and allowed to cool for 30 min at
room temperature. The slides were incubated at room
temperature for 30 min with a polyclonal anti-VEGF
antibody that detects the 189-, 165-, and 121-amino acid
splice variants of human VEGF (sc-152; titer, 1:100; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). A biotin-
streptavidin detection system (Dako, Glostrup, Denmark)
was subsequently applied using diaminobenzidine as the
chromogen. As a negative control, phosphate-buffered sa-
line or a normal rabbit immunoglobulin fraction diluted
to the same protein concentration as the primary antibody
was used. A pathologist independently evaluated the im-
munostaining. Staining was semiquantitatively assessed on
the basis of a four-grade scale (0, absence of faint mem-
brane staining in most tumor cells (<20%); 1+, membrane
staining of most tumor cells; 2+, diffuse membrane stain-
ing and cytoplasmic staining of groups of tumor cells
(<50%); and 3+, significant cytoplasmic staining in most
cells). A score of 2+ or above was considered positive [7].
Statistics
Variables were compared between the different groups
using the Mann-Whitney U and Kruskal-Wallis tests.
Independence of fitness of the categorical data was esti-
mated using the χ2 test. Recurrence-free survival rates
were calculated from the date of nephrectomy to the
Table 1 Patient characteristics in relation to without and with recurrence CCRCC
Characteristic Total Without recurrence group With recurrence group P-value
(n = 83) (n = 71) (n = 12)
Age (years)
Median [range] 67 [23-83] 67 [23-83] 65 [44-82] 0.820
Gender (%)
Male 52 (63) 48 (68) 4 (33)
Female 31 (37) 23 (32) 8 (67) 0.049
ECOG PS (%)
0 81 (98) 70 (99) 11 (92)
1 1 (1) 1 (1) 0 (0)
2 1 (1) 0 (0) 1 (8) 0.046
T stage (%)
T1 64 (77) 60 (85) 4 (33)
T2 5 (6) 4 (5) 1 (9)
T3 14 (17) 7 (10) 7 (58)
T4 0 (0) 0 (0) 0 (0) <0.001
Grade (%)
1 7 (8) 5 (7) 2 (17)
2 70 (84) 64 (90) 6 (50)
3 6 (8) 2 (3) 4 (33) <0.001
UISS risk classification (%)
Low risk 61 (73) 58 (82) 3 (25)
Intermediate risk 21 (25) 13 (18) 8 (67)
High risk 1 (2) 0 (0) 1 (8) <0.001
Histological vein invasion (%)
No 53 (64) 48 (68) 5 (42)
Yes 30 (36) 23 (32) 7 (58) 0.083
Tumor necrosis (%)
No 70 (84) 64 (90) 6 (50)
Yes 13 (16) 7 (10) 6 (50) <0.001
Symptoms (%)
No 59 (71) 52 (73) 7 (58)
Yes 24 (29) 19 (27) 5 (42) 0.292
IHC staining (%)
Grade 0 39 (47) 37 (52) 2 (17)
Grade 1+ 18 (22) 15 (21) 3 (25)
Grade 2+ 19 (23) 15 (21) 4 (33)
Grade 3+ 7 (8) 4 (6) 3 (25) 0.045
Tumor size (mm)
Median [range] 40.0 [12-120] 40.0 [12-90] 43.5 [30-120] 0.118
Hemoglobin (g/dL )
Median [range] 13.4 [8.1-17.0] 13.55 [9.6-17.0] 12.2 [8.1-14.7] 0.014
Corrected Ca (mg/dL)
Median [range] 9.30 [8.5-11.2] 9.25 [8.5-10.8] 9.35 [8.6-11.2] 0.606
CRP (mg/dL)
Median [range] 0.20 [0.0-12.4] 0.20 [0.0-12.4] 0.35 [0.0-6.2] 0.335
Serum VEGF (pg/mL)
Median [range] 299 [42-1460] 290 [42-1460] 478 [140-982] 0.038
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rate was calculated using the Kaplan-Meier method, and
the significance of comparisons between groups was mea-
sured using the log-rank test. A multivariate analysis was
performed using a Cox proportional hazards regression
model. The optimal serum VEGF value to discriminate re-
currence, calculated using receiver operating characteristic
(ROC) curve analysis. P-values of <0.05 were considered
statistically significant. All statistical analyses were per-
formed using statistical software available commercially
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Patient characteristics are shown in Table 1. Mean age
of the patients was 65.0 ± 12.4 years. The mean follow-
up duration was 52.6 ± 31.2 months (range, 3–139
months). Twelve patients (14.5%) had recurrence after
surgery. The recurrence sites were as follows: lung (9 pa-
tients, 75%), bone (2 patients, 17%) and retroperitoneum
(1 patient, 8%). In the recurrence group, four patients
(33.3%) were treated with molecular-targeted therapy
and two patients (16.7%) were treated with interferon
therapy after recurrence. Two patients were performedls and IHC tissue staining of VEGF
IHC tissue staining of VEGF
Positive group Negative group
n (%) n (%) P-value
26 57
13 (50) 39 (68)
13 (50) 18 (32) 0.107
16 (65) 48 (84)
4 (15) 1 (2)
6 (23) 8 (14)
0 (0) 0 (0) 0.023
1 (4) 6 (11)
19 (73) 51 (89)
6 (23) 0 (0) <0.001
14 (57) 47 (82)
11 (42) 10 (18)
1 (4) 0 (0) 0.014
15 (58) 38 (67)
11 (42) 19 (33) 0.430
22 (85) 48 (84)





19 (73) 52 (91)
7 (27) 5 (9) 0.043
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did not have recurrence. There was no significant associ-
ation between prophylactic interferon therapy and recur-
rence (P = 0.556). Tumor stage, pathological grade, tumor
necrosis, UISS, gender, hemoglobin, serum VEGF level
and VEGF IHC-expression were significantly associated
with recurrence (Table 1).
The median serum level of VEGF in 83 patients was
299 pg/mL (range, 42–1460 pg/mL). The serum VEGF
level in patients with recurrence was significantly higher
than in those without recurrence (P = 0.038). The serum
VEGF level was significantly associated with pathological
grade (P = 0.024), however, it was not significantly asso-
ciated with tumor stage, histological vein invasion or
UISS risk classification (P = 0.109, 0.193, and 0.282, re-
spectively) (Table 2). The cut-off value (416 pg/mL) of
serum VEGF was determined using ROC analysis. Pa-
tients with a high serum VEGF level had significantly
lower recurrence-free survival rates than those with a
low serum VEGF level (P = 0.003; Figure 1).
Expression of VEGF using IHC is shown in Figure 2.
Twenty-six patients (31.3%) were positive for VEGF ex-
pression. There was no significant association between
serum levels and IHC-expression of VEGF (IHC expres-
sion Grade 0: 313 pg/mL, Grade 1+: 325 pg/mL, Grade
2+: 248 pg/mL, Grade 3+: 507 pg/mL; P = 0.378). VEGF
IHC-expression was significantly associated with tumor
stage, tumor grade, UISS risk classification and recurrence
(Table 2). Patients positive for VEGF had significantly
lower recurrence-free survival rates than those negative
for VEGF IHC-expression (P = 0.044; Figure 3).
Tumor stage, pathological grade, histological vein in-
vasion, tumor necrosis, UISS, female gender, anemia,
CRP, serum VEGF level and VEGF IHC-expression wereFigure 1 Kaplan-Meier analysis of recurrence-free survival rates:
comparison between patients with high and low serum VEGF
levels. VEGF concentrations were determined before surgery. The
solid line represents serum VEGF >416 pg/mL (n = 22) and the dotted
line represents serum VEGF ≤416 pg/mL (n = 61). Patients with
VEGF >416 pg/mL had a significantly increased risk of recurrence
compared with those with VEGF ≤416 pg/mL (P = 0.003).significant univariate factors in predicting postoperative
recurrence. A multivariate Cox logistic regression ana-
lysis showed that the preoperative serum level of VEGF
and female gender were the only independent predictors
of recurrence after radical nephrectomy (Table 3).
Discussion
Angiogenesis is essential for tumor development and
metastasis. VEGF plays a major role in stimulating the
formation of new blood vessels in several biological pro-
cesses including tumor angiogenesis [13]. CCRCC is a
highly angiogenic tumor that secretes VEGF [14]. The
Kattan postoperative nomogram and UISS are widely
used to predict tumor recurrence after treatment of
RCC [10,15]; however, improved methods of prediction
are required, and attempts to find better prognostic cri-
teria are ongoing. This study showed that preoperative
serum levels of VEGF may be a useful predictor of post-
operative recurrence in patients with nonmetastatic
CCRCC.
Rioux-Leclercq et al. reported that the expression of
VEGF, assessed using IHC, in CCRCC tumors from 50
patients with a median follow-up of 11 months, was sig-
nificantly associated with plasma VEGF levels, measured
using an enzyme-linked immunoassay. Both expression
of VEGF, using IHC, and plasma VEGF levels were sig-
nificantly correlated with Fuhrman grade and tumor
stage. VEGF IHC-expression correlated significantly with
progression (P < 0.01); however, there was insignificant
difference in plasma VEGF levels between patients with
and without progression (P = 0.06) [16].
There are several possible explanations for the discrep-
ancy between the study by Rioux-Leclercq et al. and our
study. First, both the studies were evaluated using a
small sample size and short follow-up period. Second,
tumor size affects the amount of circulating tumor-
derived VEGF [17]; therefore, serum levels of VEGF may
be higher in patients with larger tumors even if tumor
cells express a similar level of VEGF. Third, variability in
VEGF isoforms may affect the correlation between
serum VEGF levels and expression of VEGF using IHC.
VEGF has five isoforms (VEGF206, 189, 165, 145 and
121). In the present study, only VEGF189, 165 and 121
were assessed using IHC because high expression of
these forms has been reported in RCC [18]. VEGF165
was selected for serum determination because VEGF165
and VEGF121 are the predominant isoforms secreted by
most tumors [19]. The relationship between the pattern
of VEGF isoforms synthesized in tumors and their con-
centration in the circulation remains unclear and war-
rants further study. Fourthly, bias could exist in
assessing VEGF levels in plasma or serum samples.
Serum samples contain high levels of VEGF due to its
release by activated platelets during clotting [20]. Several
Figure 2 IHC staining of VEGF in CCRCC. (A) No staining or membrane staining was observed in <20% of the tumor cells (grade 0); (B) Membrane
without cytoplasmic immunostaining of tumor cells (grade 1+); (C) Diffuse membrane and cytoplasmic staining in <50% of tumor cells (grade 2+); and
(D) Significant cytoplasmic staining in most tumor cells (grade 3+). Magnification was 400 × .
Fujita et al. BMC Research Notes 2014, 7:369 Page 6 of 9
http://www.biomedcentral.com/1756-0500/7/369studies reported a correlation between platelet counts
and serum VEGF, and higher serum VEGF levels per
platelet in cancer patients [21,22]. Niers et al. reported
that elevated plasma VEGF levels in blood samples
were highly dependent on the method of collection
and platelet VEGF content. Therefore, for the pur-
pose of avoiding platelet activation ex vivo, blood
samples were collected drop by drop without using a
tourniquet [23].
Studies have shown that elevated serum levels of VEGF
are associated with disease prognosis [6,24]. Previously,Figure 3 Kaplan-Meier analysis of recurrence-free survival rates:
comparison between patients positive and negative for VEGF
expression using IHC. The solid line represents the IHC-positive
group (n = 26), and the dotted line represents the IHC-negative group
(n = 57). The IHC-positive group had a significantly increased risk of
recurrence compared with the IHC-negative group (P = 0.044)we reported that the pretreatment serum level of VEGF
correlated with postoperative recurrence in patients with
nonmetastatic CCRCC [9]. In this study, we extended
the mean period of follow-up (33.9 ± 27.2 to 52.6 ±
31.2 months), and evaluated VEGF using both serum
analysis and immunohistochemical assay. The number of
patients with recurrence increased from 8 to 12, but
the cut-off value using ROC analysis was the same.
Jacobsen et al. reported that serum levels of VEGF,
assessed using a cut-off value of 343.5 pg/mL, as deter-
mined using the median value measured in 164 patients
with RCC including various histological subtypes, signifi-
cantly correlated with tumor stage, pathological grade and
prognosis [6]. On the other hand, Tanimoto et al. reported
that serum VEGF levels measured using the same
methodology as in the Jacobsen et al. study and assessed
using a cut-off value (400 pg/mL), as determined using
ROC analysis in 45 patients with CCRCC, were not
significantly correlated with tumor stage, pathological
grade, tumor size or prognosis [25]. With regard to the
relationship between histological subtype and serum levels
of VEGF, there was no significant difference in serum
VEGF levels between papillary RCC and CCRCC.
However, serum VEGF levels in chromophobe RCC were
found to be significantly lower than those in CCRCC [6].
The discordant result may be attributed to differences in
RCC histological subtypes in subjects and the method
used to calculate the cut-off value.
Based on IHC data, several investigators have reported
that VEGF overexpression in CCRCC was associated
with tumor stage, pathological grade, histological vein
Table 3 Univariate and multivariate analyses to predict postoperative recurrence
Variable Univariate Multivariate
Recurrence
n n (%) P-value Hazard ratio (95% CI) P-value
T stage 1 + 2 69 5 (7) 1.0 (ref)
3 + 4 14 7 (50) <0.001 4.376 (0.186–103.189) 0.360
Grade 1 + 2 77 8 (10) 1.0 (ref)
3 6 4 (67) <0.001 2.224 (0.091–54.113) 0.624
Histological No 53 5 (9) 1.0 (ref)
Vein invasion Yes 30 7 (23) 0.033 1.585 (0.248–10.120) 0.626
Tumor size <5 cm 54 7 (13)
≥5 cm 29 5 (17) 0.549
Symptoms No 59 7 (12)
Yes 24 5 (21) 0.195
Tumor necrosis No 70 6 (9) 1.0 (ref)
Yes 13 6 (46) <0.001 4.023 (0.523–30.944) 0.181
UISS Low 61 3 (5) 1.0 (ref)
Intermediate + high 22 9 (41) <0.001 7.373 (0.434–125.320) 0.170
Gender Male 52 4 (8) 1.0 (ref)
Female 31 8 (26) 0.017 13.869 (2.354–81.713) 0.004
ECOG PS 0 81 11 (14)
≥1 2 1 (50) 0.146
Age <65 48 6 (12)
(years) ≥65 35 6 (17) 0.809
Anemia No 60 6 (10) 1.0 (ref)
Yes 22 6 (27) 0.035 1.536 (0.197–11.972) 0.682
Missing 1
LDH ≤1.5 × ULN 71 11 (15)
>1.5 × ULN 2 0 (0) NA
Missing 10
Corrected Ca ≤10 71 10 (14)
(mg/dL) >10 8 1 (12) 0.781
Missing 4
CRP ≤1.0 70 8 (11) 1.0 (ref)
(mg/dL) >1.0 12 4 (33) 0.015 0.476 (0.032–7.168) 0.591
Missing 1
Serum VEGF ≤416 61 4 (7) 1.0 (ref)
(pg/mL) >416 22 8 (36) 0.003 18.059 (1.853–176.019) 0.013
IHC staining Negative 57 5 (9) 1.0 (ref)
Positive 26 7 (27) 0.044 1.130 (0.160–7.967) 0.902
NA: not available, ref: reference.
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reported that VEGF expression using IHC in CCRCC
was not significantly correlated with prognosis [26]. This
discrepancy in IHC results could be due to several fac-
tors including differences in fixation, scoring and stain-
ing methods [7,8,26].Predictive factors of recurrence after nephrectomy in
patients with RCC include anatomical (TNM classifica-
tion), histological (pathological grade, histological vein
invasion and tumor necrosis), clinical (symptoms and
performance status) and biochemical (level of CRP) fea-
tures [10-12,15,27,28]. A major prognostic model for
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Fuhrman grade and ECOG PS [10]. In our study, symp-
toms, ECOG PS and tumor size were not significant pre-
dictive factors of postoperative recurrence in patients with
nonmetastatic CCRCC. The present study showed that fe-
male patients had a significantly poorer recurrence-free
survival rate than male patients. However, Leibovich et al.
reported no significant relationship between gender and
prognosis in 1671 patients with CCRCC [27]. The gender
difference in postoperative recurrence in our study may
be due to the small number of enrolled patients and the
retrospective nature of our study.
In RCC, few studies have investigated VEGF as a pre-
dictor of postoperative recurrence. However, several
studies in patients with esophageal, hepatocellular and
colorectal carcinomas showed that elevation of serum
VEGF levels might be a predictor for poor recurrence-
free survival [29-31]. The present study had some limita-
tions. First, the relatively small sample size may produce
false-positive results, or over-estimate the magnitude of
an association. Second, the short follow-up time may be
insufficient to observe recurrence. Third, this was a
retrospective study, which was susceptible to selection
bias. A larger study and one with more balanced groups
(i.e. patients with and without recurrence) will produce
more precise estimates. Further large prospective studies
are needed to confirm our results.
Conclusions
Our study showed that measurement of preoperative
VEGF serum levels in patients with nonmetastatic CCRCC
may be more useful than using IHC to assess VEGF ex-
pression in tumor tissues for prediction of postoperative
recurrence after nephrectomy.
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